ERBB3 and thyroid cancer: The RAF inhibitor PLX4720 in melanoma enhanced erbB3 expression through the transcription factor, FOXD3 [71], whereas inhibition of RAF in thyroid cancers with vemurafenib (PLX4032) induced erbB3 transcription via decreased promoter occupancy by the transcriptional repressors C-terminal binding protein 1 and 2 (CtBP1/2) [72].